p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer.

In previous studies, we noted that overexpression of hypoxia-inducible factor (HIF)-1alpha in breast cancer, especially the diffuse form, does not always lead to functional activation of its downstream genes. Transcriptional activity of HIF-1 may be repressed by p53 through competition for transcriptional coactivators such as p300. The aim of this study was therefore to explore the role of p53 and p300 in relation to overexpression of HIF-1alpha and activation of HIF-1 downstream genes in invasive breast cancer. p300 immunohistochemistry was performed in a group of 183 early-stage invasive breast cancers, and related to p53 accumulation, overexpression of HIF-1alpha, and several HIF-1 downstream genes. p300 was expressed in varying degrees in 84% of invasive breast cancers. p300 staining intensity correlated positively with HIF-1alpha expression (P = .04), p53 accumulation (P = .001), and overexpression of glucose transporter 1 (GLUT-1) (P < .001), a glucose transporter downstream target gene of HIF-1. GLUT-1 levels were significantly associated with p300 in HIF-1alpha positive patients (P = .02). p53 accumulation significantly positively correlated with carbonic anhydrase IX (CAIX)/GLUT-1 coexpression in HIF-1alpha-positive patients (P = .007). p53 accumulation/high p300 levels, the most favorable situation for HIF-1 downstream activation, were significantly associated with GLUT-1 overexpression (P = .01) and coexpression of CAIX/GLUT-1 (P = .03), compared with low p53/low p300 levels, the most unfavorable situation for HIF-1 downstream activation. p300 is a cofactor highly associated with p53 accumulation and HIF-1alpha levels in invasive breast cancer. Furthermore, low levels of p300 may explain absence of downstream effects in HIF-1alpha-overexpressing cancers, an effect that seems to be enhanced by wild-type levels of p53. This underlines the importance of p300 levels and p53 accumulation in the HIF-1-regulated response toward hypoxia.

[1]  G. Semenza,et al.  Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression , 2000, Critical reviews in biochemistry and molecular biology.

[2]  G. Semenza,et al.  HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.

[3]  G. Semenza.  HIF-1 and mechanisms of hypoxia sensing. , 2001, Current opinion in cell biology.

[4]  P. V. van Diest,et al.  Expression of hypoxia-inducible factor-1α and cell cycle proteins in invasive breast cancer are estrogen receptor related , 2004, Breast Cancer Research.

[5]  S. Bhattacharya,et al.  An essential role for p300/CBP in the cellular response to hypoxia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Pouysségur,et al.  Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. , 2005, Cellular signalling.

[7]  P. V. van Diest,et al.  Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma , 2003, Cancer.

[8]  D. Peet,et al.  Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch , 2002, Science.

[9]  P. V. van Diest,et al.  Mutation analysis of the HIF-1alpha oxygen-dependent degradation domain in invasive breast cancer. , 2005, Cancer genetics and cytogenetics.

[10]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[11]  Jacques Côté,et al.  The diverse functions of histone acetyltransferase complexes. , 2003, Trends in genetics : TIG.

[12]  A. Harris,et al.  Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer , 2005, Journal of Clinical Pathology.

[13]  G. Semenza,et al.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. , 1996, The American journal of physiology.

[14]  C. Harris,et al.  Distinct pattern of p53 phosphorylation in human tumors , 2001, Oncogene.

[15]  Horst Buerger,et al.  No Amplifications of Hypoxia-Inducible Factor-1α Gene in Invasive Breast Cancer: A Tissue Microarray Study , 2004, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[16]  D. Mottet,et al.  Is HIF-1α a pro- or an anti-apoptotic protein? ☆ , 2002 .

[17]  L. Neckers,et al.  Stabilization of wild-type p53 by hypoxia-inducible factor 1α , 1998, Nature.

[18]  Yoichi Taya,et al.  Regulation of p53 by Hypoxia: Dissociation of Transcriptional Repression and Apoptosis from p53-Dependent Transactivation , 2001, Molecular and Cellular Biology.

[19]  T. Unterman,et al.  The Transcription Factors HIF-1 and HNF-4 and the Coactivator p300 Are Involved in Insulin-regulated Glucokinase Gene Expression via the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway* , 2004, Journal of Biological Chemistry.

[20]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[21]  M. Hung,et al.  Involvement of Co-activator p300 in the Transcriptional Regulation of the HER-2/neu Gene* , 1997, The Journal of Biological Chemistry.

[22]  Margaret Ashcroft,et al.  Negative and positive regulation of HIF-1: a complex network. , 2005, Biochimica et biophysica acta.

[23]  I. Ellis,et al.  Pathology and breast screening , 1990, Histopathology.

[24]  T. Fojo,et al.  p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* , 1998, The Journal of Biological Chemistry.

[25]  L. Kasper,et al.  Mammalian Gene Expression Program Resiliency: The Roles of Multiple Coactivator Mechanisms in Hypoxia–Responsive Transcription , 2006, Cell cycle.

[26]  Andrew L. Kung,et al.  Suppression of tumor growth through disruption of hypoxia-inducible transcription , 2000, Nature Medicine.

[27]  R. Goodman,et al.  CREB-binding Protein and p300 in Transcriptional Regulation* , 2001, The Journal of Biological Chemistry.

[28]  B. Brüne,et al.  Tumor hypoxia and cancer progression. , 2006, Cancer letters.

[29]  A. Dejean,et al.  Nuclear and unclear functions of SUMO , 2003, Nature Reviews Molecular Cell Biology.

[30]  D. Tindall,et al.  p300 in prostate cancer proliferation and progression. , 2003, Cancer research.

[31]  P. V. van Diest,et al.  Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment , 2002, British Journal of Cancer.

[32]  Gerhard Wagner,et al.  Structural basis for negative regulation of hypoxia-inducible factor-1α by CITED2 , 2003, Nature Structural Biology.

[33]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[34]  Moon-Kyoung Bae,et al.  Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation , 2002, Cell.

[35]  E. Kubista,et al.  Expression of Sex Steroid Receptors and their Co-Factors in Normal and Malignant Breast Tissue: AIB1 is a Carcinoma-Specific Co-Activator , 2003, Breast Cancer Research and Treatment.

[36]  G. Zambetti,et al.  The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. , 2001, Gene.

[37]  R. Henriksson,et al.  p53 and vascular‐endothelial‐growth‐factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma , 2000, International journal of cancer.

[38]  D. Livingston,et al.  Binding and modulation of p53 by p300/CBP coactivators , 1997, Nature.

[39]  B. Brüne,et al.  p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). , 2004, The Biochemical journal.

[40]  N. Sang,et al.  MAPK Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300* , 2003, The Journal of Biological Chemistry.

[41]  B. Brüne,et al.  HIF‐1 and p53: communication of transcription factors under hypoxia , 2004, Journal of cellular and molecular medicine.

[42]  D. Mukhopadhyay,et al.  Protein Kinase C ζ Transactivates Hypoxia-Inducible Factor α by Promoting Its Association with p300 in Renal Cancer , 2004, Cancer Research.

[43]  J. Cleveland,et al.  Two transactivation mechanisms cooperate for the bulk of HIF‐1‐responsive gene expression , 2005, The EMBO journal.

[44]  G. Semenza,et al.  Levels of Hypoxia-Inducible Factor-1α During Breast Carcinogenesis , 2001 .

[45]  L. Sobin,et al.  Histological Typing of Breast Tumors 1 , 1982 .

[46]  F. Ismail-Beigi,et al.  Regulation of glut1 mRNA by Hypoxia-inducible Factor-1 , 2001, The Journal of Biological Chemistry.

[47]  J. Savulescu,et al.  No consent should be needed for using leftover body material for scientific purposes , 2002, BMJ : British Medical Journal.

[48]  C. Caldas,et al.  p300/CBP and cancer , 2004, Oncogene.

[49]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.